New medication after CAR T-cell therapy for aggressive lymphoma

Plain-English translation of NCT06271057 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a medication called given after CAR T-cell therapy, a powerful cancer treatment that uses your own immune cells to fight lymphoma. Researchers want to see if adding this medication can help keep the cancer from coming back in patients whose aggressive B-cell lymphoma has already resisted other treatments. The study will enroll about 65 patients over 18 months and track how well this combination works.

CAR T-cell therapy works well for some patients with aggressive lymphoma, but some patients relapse—meaning the cancer comes back. Researchers believe that giving the medication afterward might boost the immune system's ability to keep the cancer under control long-term.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with aggressive B-cell lymphoma (such as diffuse large B-cell lymphoma) that has come back or did not respond to prior treatments
you are eligible to receive CAR T-cell therapy and have been approved by your tumor board for it as your next line of treatment
you have adequate kidney and liver function based on blood tests
you have a tumor burden measured as greater than 80 milliliters on a PET scan just before starting CAR T-cell therapy
if you are a woman who can become pregnant, you are able and willing to use effective contraception during treatment and for at least 28 days after your last dose

You likely don't qualify if…

you have a history of another cancer (except non-melanoma skin cancer) unless you have been cancer-free for at least 3 years
you have an uncontrolled infection or are currently being treated with intravenous antibiotics
you have HIV infection
your kidney or liver function is severely impaired

What participation looks like

You would first receive CAR T-cell therapy as scheduled. Then, starting 5 days after your CAR T-cell infusion, you would take by mouth once a week for 24 weeks (6 cycles of 4 weeks each). During this time, you will have regular visits for blood tests, scans, and medical check-ins to monitor how well the treatment is working and watch for any side effects. The study team will assess your response using imaging tests about 3 months after your CAR T-cell infusion.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

New medication after CAR T-cell therapy for aggressive lymphoma

What is this trial?

Do you qualify?

What participation looks like

Trial locations